Baricitinib plus remdesivir shows promise in hospitalized patients

Dec 14, 2020 - 03:18 PM
FDA product update

Combining the anti-inflammatory drug baricitinib with the antiviral drug remdesivir reduced the median recovery time for hospitalized COVID-19 patients from eight to seven days, according to clinical trial results published Friday in the New England Journal of Medicine.

The therapy appeared to benefit patients requiring high-flow oxygen or non-invasive ventilation most, reducing their median time to recovery from 18 days to 10 days, researchers said.

The clinical trial is the second in the National Institutes of Health Adaptive COVID-19 Treatment Trial, a study to evaluate therapeutics for people hospitalized with COVID-19. 

The Food and Drug Administration last month authorized the emergency use of baricitinib in combination with remdesivir to treat suspected or laboratory confirmed COVID-19 in certain hospitalized patients requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.

Related News Articles

Blog
RAND 5.0 – The Health Policy Equivalent of Groundhog Day
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
CDC encourages older adults to get additional COVID-19 vaccine dose 
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
NASEM releases evidence review on COVID-19 vaccine safety
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
FDA approves combo test for flu, COVID-19; alerts providers to medical device risks 
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
CDC recommends additional dose of updated COVID-19 vaccine for older adults
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
FDA: Paxlovid no longer labeled for emergency use after March 8
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…